Aerie Prescription drugs Proclaims New Worker Inducement Grant
Pharmaceuticals

Aerie Prescription drugs Proclaims New Worker Inducement Grant


Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium right here.


DURHAM, N.C.–(BUSINESS WIRE)–
Aerie Prescription drugs, Inc. (NASDAQ: AERI), a pharmaceutical firm targeted on the invention, improvement, and commercialization of first-in-class ophthalmic therapies for the therapy of sufferers with open-angle glaucoma, ocular floor ailments and retinal ailments right now introduced that the compensation committee of Aerie Pharmaceutical’s board of administrators granted one new worker an award totaling 16,900 inventory choices that may vest over 4 years, with 25% vesting on the primary anniversary of the rent date and the rest vesting ratably on every of the following 36 month-to-month anniversaries of the rent date. This award was made outdoors of Aerie’s stockholder-approved fairness incentive plan and was authorised by the Firm’s unbiased administrators as an inducement materials to the worker getting into into employment with the Firm in reliance on Nasdaq Itemizing Rule 5635(c)(4), which requires this public announcement.

About Aerie Prescription drugs, Inc.

Aerie is a pharmaceutical firm targeted on the invention, improvement, and commercialization of first-in-class ophthalmic therapies for the therapy of sufferers with eye ailments and situations together with open-angle glaucoma, dry eye, diabetic macular edema (DME) and moist age-related macular degeneration (moist AMD). Aerie’s first novel product, Rhopressa® (netarsudil ophthalmic resolution) 0.02%, a once-daily eye drop authorised by the U.S. Meals and Drug Administration (FDA) for the discount of elevated intraocular stress (IOP) in sufferers with open-angle glaucoma or ocular hypertension, was launched in the USA in April 2018. In scientific trials of Rhopressa®, the most typical antagonistic reactions had been conjunctival hyperemia, corneal verticillata, instillation web site ache, and conjunctival hemorrhage. Extra details about Rhopressa®, together with the product label, is accessible at www.rhopressa.com. Aerie’s second novel product for the discount of elevated IOP in sufferers with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic resolution (0.005%)), was launched in the USA in Could 2019. In scientific trials of Rocklatan®, the most typical antagonistic reactions had been conjunctival hyperemia, corneal verticillata, instillation web site ache, and conjunctival hemorrhage. Extra details about Rocklatan®, together with the product label, is accessible at www.rocklatan.com. Extra data on Aerie Prescription drugs is accessible at www.aeriepharma.com.

Ahead-Wanting Statements

This press launch comprises forward-looking statements for functions of the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. We might, in some circumstances, use phrases akin to “predicts,” “believes,” “potential,” “proposed,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “might,” “may,” “would possibly,” “will,” “ought to,” “exploring,” “pursuing” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Ahead-looking statements on this launch embrace statements relating to our intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues: the length and severity of the coronavirus illness (COVID-19) outbreak and its variants, together with the affect on our scientific and business operations, demand for our merchandise and monetary outcomes and situation of our world provide chains; our expectations relating to the commercialization and manufacturing of Rhopressa®, Rocklatan®, Rhokiinsa® and Roclanda® or any product candidates or future product candidates., FDA approval of Rhopressa® and Rocklatan® doesn’t assure FDA approval of our product candidates or any future product candidates and there might be no assurance that we are going to obtain FDA approval for our product candidates or any future product candidates. Moreover, the acceptance of an Investigational New Drug Functions by the FDA for our product candidates doesn’t assure FDA approval of such product candidates and the outcomes of later scientific trials for our product candidates is probably not adequate to submit a New Drug Utility (NDA) with the FDA or to obtain FDA approval. By their nature, forward-looking statements contain dangers and uncertainties as a result of they relate to occasions, aggressive dynamics, business change and different components past our management, and depend upon regulatory approvals and financial and different environmental circumstances that will or might not happen sooner or later or might happen on longer or shorter timelines than anticipated. We talk about many of those dangers in larger element underneath the heading “Threat Elements” within the quarterly and annual stories that we file with the Securities and Change Fee (SEC). Ahead-looking statements usually are not ensures of future efficiency and our precise outcomes of operations, monetary situation and liquidity, and the event of the business wherein we function might differ materially from the forward-looking statements contained on this press launch. Any forward-looking statements that we make on this press launch converse solely as of the date of this press launch. We assume no obligation to replace our forward-looking statements whether or not on account of new data, future occasions or in any other case, after the date of this press launch.

Aerie Prescription drugs Proclaims New Worker Inducement Grant

Media:

Carolyn McAuliffe

[email protected]

(949) 526-8733

Buyers:

LifeSci Advisors on behalf of Aerie Prescription drugs, Inc.

Hans Vitzthum

[email protected]

(617) 430-7578

Supply: Aerie Prescription drugs, Inc.